February 24, 2021
The Rosen Law Firm will represent a proposed class of investors in a suit alleging Biogen Inc. and three of its executives misrepresented the odds of approval for one of the pharmaceutical company's drugs with the U.S. Food and Drug Administration.
January 13, 2021
The Rosen Law Firm PA, Lowey Dannenberg PC and Pomerantz LLP all want to represent a proposed class of investors in a securities fraud suit in California federal court alleging Biogen Inc. and three of its executives misrepresented the odds of success that one of the pharmaceutical company's drugs has with the U.S. Food and Drug Administration.
November 13, 2020
Biogen Inc. investors on Friday hit the drugmaker with a putative class action claiming the company and its top brass misled shareholders about the effectiveness of aducanumab, a proposed drug for treating early Alzheimer's disease.